Gadopiclenol

Gadopiclenol
Clinical data
Trade names	Elucirem, Vueway
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Gadopiclenol;
Routes of; administration	Intravenous
ATC code	V08CA12 (WHO) ;
Legal status
Legal status	US: ℞-only[1][2];
Pharmacokinetic data
Metabolism	None[1]
Excretion	Kidneys[1]
Identifiers
	IUPAC name 2-[3,9-bis[1-carboxylato-4-(2,3-dihydroxypropylamino)-4-oxobutyl]-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]-5-(2,3-dihydroxypropylamino)-5-oxopentanoate;gadolinium(3+);
CAS Number	933983-75-6;
PubChem CID	16223405;
ChemSpider	17350646;
UNII	S276568KOY;
KEGG	D12435;
Chemical and physical data
Formula	C35H54GdN7O15
Molar mass	970.10 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Gd+3].OCC(O)CNC(=O)CCC(N1CCN(Cc2cccc(CN(CC1)C(CCC(=O)NCC(O)CO)C(=O)[O-])n2)C(CCC(=O)NCC(O)CO)C(=O)[O-])C(=O)[O-];
	InChI InChI=1S/C35H57N7O15.Gd/c43-19-24(46)14-36-30(49)7-4-27(33(52)53)40-10-12-41(28(34(54)55)5-8-31(50)37-15-25(47)20-44)17-22-2-1-3-23(39-22)18-42(13-11-40)29(35(56)57)6-9-32(51)38-16-26(48)21-45;/h1-3,24-29,43-48H,4-21H2,(H,36,49)(H,37,50)(H,38,51)(H,52,53)(H,54,55)(H,56,57);/q;+3/p-3; Key:GNRQMLROZPOLDG-UHFFFAOYSA-K;

Gadopiclenol, sold under the brand name Elucirem among others, is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body.[1] Gadopiclenol is a paramagnetic macrocyclic non-ionic complex of gadolinium.[1]

Gadopiclenol was approved for medical use in the United States in September 2022.[1][3][4]

Names

Gadopiclenol is the international nonproprietary name (INN).[5]

References

"Elucirem- gadopiclenol injection". DailyMed. 12 October 2022. Retrieved 16 October 2022.
"Drug Approval Package: Elucirem". U.S. Food and Drug Administration (FDA). 20 October 2022. Retrieved 4 December 2022.
"Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem (Gadopiclenol)" (Press release). Guerbet. 21 September 2022. Retrieved 16 October 2022 – via GlobeNewswire.
"Novel Drug Approvals for 2022". U.S. Food and Drug Administration (FDA). 3 October 2022. Retrieved 16 October 2022. This article incorporates text from this source, which is in the public domain.
World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.

External links

Clinical trial number NCT03996447 for "Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PICTURE)" at ClinicalTrials.gov
Clinical trial number NCT03986138 for "Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) (PROMISE)" at ClinicalTrials.gov

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Elucirem_FDA_label-1] "Elucirem- gadopiclenol injection". DailyMed. 12 October 2022. Retrieved 16 October 2022.

[2] "Drug Approval Package: Elucirem". U.S. Food and Drug Administration (FDA). 20 October 2022. Retrieved 4 December 2022.

[3] "Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem (Gadopiclenol)" (Press release). Guerbet. 21 September 2022. Retrieved 16 October 2022 – via GlobeNewswire.

[4] "Novel Drug Approvals for 2022". U.S. Food and Drug Administration (FDA). 3 October 2022. Retrieved 16 October 2022. This article incorporates text from this source, which is in the public domain.

[5] World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.